PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ACRV vs. BVS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ACRV and BVS is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

ACRV vs. BVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Acrivon Therapeutics Inc. Common Stock (ACRV) and Bioventus Inc. (BVS). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-38.89%
4.45%
ACRV
BVS

Key characteristics

Sharpe Ratio

ACRV:

0.29

BVS:

1.88

Sortino Ratio

ACRV:

1.44

BVS:

2.86

Omega Ratio

ACRV:

1.16

BVS:

1.36

Calmar Ratio

ACRV:

0.39

BVS:

1.63

Martin Ratio

ACRV:

1.12

BVS:

8.84

Ulcer Index

ACRV:

29.18%

BVS:

14.63%

Daily Std Dev

ACRV:

111.48%

BVS:

69.01%

Max Drawdown

ACRV:

-85.34%

BVS:

-95.18%

Current Drawdown

ACRV:

-77.11%

BVS:

-46.28%

Fundamentals

Market Cap

ACRV:

$165.33M

BVS:

$674.60M

EPS

ACRV:

-$2.66

BVS:

-$0.61

Total Revenue (TTM)

ACRV:

$0.00

BVS:

$419.64M

Gross Profit (TTM)

ACRV:

-$424.00K

BVS:

$281.75M

EBITDA (TTM)

ACRV:

-$64.02M

BVS:

$17.95M

Returns By Period

In the year-to-date period, ACRV achieves a -11.79% return, which is significantly lower than BVS's -1.71% return.


ACRV

YTD

-11.79%

1M

-8.13%

6M

-42.22%

1Y

41.22%

5Y*

N/A

10Y*

N/A

BVS

YTD

-1.71%

1M

2.79%

6M

13.16%

1Y

126.81%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ACRV vs. BVS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACRV
The Risk-Adjusted Performance Rank of ACRV is 6262
Overall Rank
The Sharpe Ratio Rank of ACRV is 5656
Sharpe Ratio Rank
The Sortino Ratio Rank of ACRV is 6868
Sortino Ratio Rank
The Omega Ratio Rank of ACRV is 6363
Omega Ratio Rank
The Calmar Ratio Rank of ACRV is 6363
Calmar Ratio Rank
The Martin Ratio Rank of ACRV is 5959
Martin Ratio Rank

BVS
The Risk-Adjusted Performance Rank of BVS is 8989
Overall Rank
The Sharpe Ratio Rank of BVS is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of BVS is 9090
Sortino Ratio Rank
The Omega Ratio Rank of BVS is 8787
Omega Ratio Rank
The Calmar Ratio Rank of BVS is 8686
Calmar Ratio Rank
The Martin Ratio Rank of BVS is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ACRV vs. BVS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Acrivon Therapeutics Inc. Common Stock (ACRV) and Bioventus Inc. (BVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ACRV, currently valued at 0.29, compared to the broader market-2.000.002.000.291.88
The chart of Sortino ratio for ACRV, currently valued at 1.44, compared to the broader market-4.00-2.000.002.004.006.001.442.86
The chart of Omega ratio for ACRV, currently valued at 1.16, compared to the broader market0.501.001.502.001.161.36
The chart of Calmar ratio for ACRV, currently valued at 0.39, compared to the broader market0.002.004.006.000.393.66
The chart of Martin ratio for ACRV, currently valued at 1.12, compared to the broader market0.0010.0020.0030.001.128.84
ACRV
BVS

The current ACRV Sharpe Ratio is 0.29, which is lower than the BVS Sharpe Ratio of 1.88. The chart below compares the historical Sharpe Ratios of ACRV and BVS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
0.29
1.88
ACRV
BVS

Dividends

ACRV vs. BVS - Dividend Comparison

Neither ACRV nor BVS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ACRV vs. BVS - Drawdown Comparison

The maximum ACRV drawdown since its inception was -85.34%, smaller than the maximum BVS drawdown of -95.18%. Use the drawdown chart below to compare losses from any high point for ACRV and BVS. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-77.11%
-24.73%
ACRV
BVS

Volatility

ACRV vs. BVS - Volatility Comparison

Acrivon Therapeutics Inc. Common Stock (ACRV) has a higher volatility of 29.64% compared to Bioventus Inc. (BVS) at 9.06%. This indicates that ACRV's price experiences larger fluctuations and is considered to be riskier than BVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
29.64%
9.06%
ACRV
BVS

Financials

ACRV vs. BVS - Financials Comparison

This section allows you to compare key financial metrics between Acrivon Therapeutics Inc. Common Stock and Bioventus Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab